News

News 2017-11-19T23:06:00+00:00

ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 12 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors. Arix also announces, David U’Prichard is retiring from the Board, effective immediately. [...]

September 13th, 2018|

Changes announced to executive team to accelerate growth and strategy

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 4 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces planned changes to its executive team to prepare for its next phase of growth and development. Dr Joe Anderson, who has served as Chief Executive Officer of Arix [...]

September 4th, 2018|

Arix Bioscience announces first VIPE investment

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014  Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine Oxidase drug discovery platform First Venture Investment in Public Equity (VIPE) led by Arix, taking core portfolio to 14 companies [...]

August 6th, 2018|

Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018 LONDON, 30 July, 2018: Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today announces its interim results for the period ended 30 June 2018. Financial highlights ▪ £35.6m net [...]

July 30th, 2018|

Autolus announces closing of IPO

LONDON, 26 June 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its largest Group Business holding Autolus Therapeutics plc (“Autolus”) has today announced the closing of its previously announced initial public offering (“IPO”) in the United States of 10,147,059 American Depositary Shares ("ADSs"), representing 10,147,059 ordinary shares, at an initial public offering price of $17.00 [...]

June 26th, 2018|

Autolus Announces Pricing of Initial Public Offering

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 22 June 2018 Second public listing of an Arix company, approximately two years after Arix inception Autolus is Arix’s largest holding, accounting for 24.7% of invested and committed capital to date* Arix agrees to invest $7.2 million (£5.5 million)** in IPO to retain a stake of 8.2% in Autolus [...]

June 22nd, 2018|

Update on Autolus proposed initial public offering in the United States

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 8 June 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its largest Group Business holding Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”) has filed an amended registration statement on Form F-1 with the U.S. [...]

June 8th, 2018|

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

LONDON, 31 May 2018: Arix Bioscience plc (LSE: ARIX) (“Arix” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Lord Hutton is stepping down from his position as a Non-Executive Director of Arix Bioscience.   Jonathan Peacock, Chairman of Arix Bioscience, said: “It has been a great pleasure to work with Lord Hutton over the last two years. [...]

May 31st, 2018|

Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases

Announces formation of LAB591, an academic “BRIDGE” collaboration focused on creating and supporting new companies in oncology and infectious diseases Collaboration combines Arix’s business building expertise with one of the world’s premier cancer research centres and Evotec’s drug discovery expertise Further enhances Arix’s broad deal-sourcing capabilities LONDON, 31 May 2018: Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX) a global healthcare and life science company [...]

May 31st, 2018|

Iterum Therapeutics plc Closes Initial Public Offering

LONDON, 30 May 2018 Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today notes that its Group Business Iterum Therapeutics plc (“Iterum”, NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today closed its initial public offering of 6,150,000 of its ordinary shares at an initial offering price to [...]

May 30th, 2018|